Validation of a quantitative SPR assay for recombinant FVIII.
Surface plasmon resonance was employed to establish a quantitative assay for recombinant FVIII (rFVIII) products using rFVIII as standard. The anti-FVIII monoclonal antibody ESH4 was immobilized onto a carboxymethyldextran surface. A range of rFVIII concentrations were injected over the surface and the binding response enhanced by the addition of a further monoclonal antibody ESH8. Validation using National Institute of Biological Standards and Controls (NIBSC) sixth International rFVIII concentrate standard gave inter- and intra-assay coefficient of variations (CVs) of 7.5 and 3.68% respectively for ESH4-rFVIII binding alone. Enhancement of the binding signal by secondary addition of ESH8 produced inter- and intra-assay CVs of 2.75 and 1.5%. The ESH4 immobilized chip was found to retain binding capacity following regeneration for at least 75 cycles. The assay was found to be unsuitable for quantitation of plasma derived FVIII product but may prove useful for monitoring of rFVIII production.
McCormick
A N
AN
The Haemophilia Centre, St Thomas' Hospital, London, UK. aine.mccormick@gstt.sthames.nhs.uk
Leach
M E
ME
Savidge
G
G
Alhaq
A
A
D000911:Antibodies, Monoclonal / Q000276:immunology; D005169:Factor VIII / Q000032:analysis* / Q000276:immunology; D006801:Humans; D040081:Protein Array Analysis / Q000379:methods; D011485:Protein Binding / Q000276:immunology; D011994:Recombinant Proteins / Q000032:analysis / Q000276:immunology; D012015:Reference Standards; D015203:Reproducibility of Results; D020349:Surface Plasmon Resonance / Q000379:methods
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII